The most recent short interest data has been released for the 02/28/2017 settlement date, which shows a 2,019,716 share decrease in total short interest for Insys Therapeutics Inc (INSY), to 11,726,537, a decrease of 14.69% since 02/15/2017. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded. The number of shares short is then compared to the average daily volume, in order to calculate the total number of trading days (at the average volume) it would take to close out all of the open short positions if every share traded represented a short position being closed. Average daily volume for INSY at the 02/28/2017 settlement increased to 1,736,162, as compared to 963,920 at the 02/15/2017 report. That brought "days to cover" down to 6.75, a 52.64% decrease from the 14.26 days to cover calculated at the previous short interest data release.The below chart shows the historical "days to cover" for INSY at previous short interest release dates: A decreased "days to cover" value could indicate that short sellers are no longer expecting the same decline in stock price they once were, or it could also indicate a long bet elsewhere was closed where INSY had been shorted as a hedge. The chart below shows the one year performance of INSY shares, versus its 200 day moving average. Looking at this chart, INSY's low point in its 52 week range is $8.70 per share, with $21.22 as the 52 week high point — that compares with a last trade of $10.92. According to the ETF Finder at ETF Channel, INSY makes up 2.20% of the PowerShares Dynamic Biotechnology & Genome Portfolio ETF (PBE) which is lower by about 0.2% on the day Friday.
More from Stocks
Boeing Slumps After Report Says Planemaker May Have Misled FAA on 737 MAX
Boeing shares traded sharply lower Friday after a report said the Federal Aviation Administration demanded the planemaker turn over internal communications that questioned the safety of software linked to the grounded 737 MAX jet.
Jim Cramer Explains Why Investors Should Keep an Eye on Brexit
Investors need to keep a close eye on Brexit.
Beyond Meat Tumbles Amid Analyst Concerns Over Competition
Beyond Meat's stock price takes a hit Friday after analysts raise concerns about stiffer competition ahead in the plant-based meat sector as giants like Tyson and Kellogg muscle in.